Ionis Pharmaceuticals IONS Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's operating lease liabilities?
- Ionis Pharmaceuticals (IONS) reported operating lease liabilities of $259.22M in Q1 2026.
- How has Ionis Pharmaceuticals's operating lease liabilities changed year-over-year?
- Ionis Pharmaceuticals's operating lease liabilities increased by 62.6% year-over-year, from $159.39M to $259.22M.
- What is the long-term trend for Ionis Pharmaceuticals's operating lease liabilities?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's operating lease liabilities has grown at a 91.7% compound annual growth rate (CAGR), from $19.43M to $262.38M.
- What does operating lease liabilities mean?
- The long-term portion of rent and lease payments for facilities.
- How do you interpret operating lease liabilities?
- Changes reflect shifts in the company's physical footprint and long-term operational capacity requirements.
- How does operating lease liabilities compare across companies?
- Standardized under lease accounting rules, allowing for direct comparison of facility commitments across peers.